Pharmadoctor CEO Graham Thoms told The BMJ that Pharmadoctor only aimed to inform patients about Wegovy and that it had kept the blog post online because the MHRA hadnt required it be taken down
University of Oklahoma researcher Elizabeth Wellberg, Ph.D., is the senior author of a review article in The Journal of Clinical Investigation that gathers current research evidence about the effects of GLP-1 drugs on cancer risk
So, it's a double-edged sword there, said Dr
In addition, so-called secondary formations develop due to the chronic irritation
This is the same receptor targeted by Wegovy (semaglutide) and Mounjaro (tirzepatide)
Red flags requiring urgent evaluation include new focal weakness, gait disturbance, bowel or bladder dysfunction, rapidly progressive symptoms, or fever in immunocompromised patients